NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

刺蝟信號抑制劑的全球市場:2019年∼2023年

Hedgehog Pathway Inhibitors Market by Product and Geography - Global Forecast and Analysis 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 910719
出版日期 內容資訊 英文 135 Pages
訂單完成後即時交付
價格
刺蝟信號抑制劑的全球市場:2019年∼2023年 Hedgehog Pathway Inhibitors Market by Product and Geography - Global Forecast and Analysis 2019-2023
出版日期: 2019年09月05日內容資訊: 英文 135 Pages
簡介

全球刺蝟信號抑制劑市場上,基底細胞癌(BCC)及急性淋巴性白血病(AML)的高風險要素,老年人口的增加,BCC及AML的認識的高漲等成為成長促進因素,在預測期間內預計將以11%以上的年複合成長率擴大。但,替代品的可得性,臨床試驗的失敗,及藥物抗性等要素,可能妨礙在預測期間內刺蝟信號抑制劑產業的成長。

本報告提供全球刺蝟信號抑制劑市場相關調查分析,市場規模及成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 調查範圍

  • 簡介1
  • 簡介2
  • 美金的貨幣換算比率

第3章 市場情形

  • 市場生態系統
  • 市場特徵
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模(2018年)
  • 市場規模及預測(2018年∼2023年)

第5章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 競爭對手的威脅
  • 市場情況

第6章 市場區隔:各產品

  • 市場區隔:各產品
  • 各產品比較:市場規模及預測(2018年∼2023年)
  • 基底細胞癌(BCC)
  • 急性淋巴性白血病(AML)
  • 市場機會:各產品

第7章 各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模及預測(2018年∼2023年)
  • 北美
  • 歐洲
  • 亞洲
  • 其他地區
  • 主要國家
  • 市場機會

第8章 成長要素與課題

  • 市場成長要素
  • 市場課題

第9章 市場趨勢

  • 再利用製劑的開發
  • 策略性聯盟
  • 癌症相關的研究的財政支援

第10章 業者情勢

  • 概要
  • 創造性破壞狀況
  • 競爭方案

第11章 供應商分析

  • 交易廠商
  • 供應商分類
  • 供應商的市場定位
  • F. Hoffmann-La Roche Ltd.
  • Inhibitor Therapeutics Inc.
  • MAX BioPharma Inc.
  • Mayne Pharma Group Ltd.
  • PellePharm Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.

第12章 附錄

  • 調查方法
  • 簡稱的清單
  • 供應商的市場定位定義

第13章 關於TECHNAVIO

目錄
Product Code: IRTNTR31997

About this market

Technavio's hedgehog pathway inhibitors market analysis considers sales from both basal cell carcinoma (BCC) and acute lymphoblastic leukemia (AML) products. Our analysis also considers the sales of hedgehog pathway inhibitors in Asia, Europe, North America, and ROW. In 2018, the BCC segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the growing geriatric population and high prevalence of BBC will play a significant role in the BCC segment to maintain its market position. Also, our global hedgehog pathway inhibitors market report looks at factors such as high-risk factors for BCC and AML, growth of geriatric population, and increasing awareness about BCC and AML. However, availability of substitutes, clinical trial failures, and drug resistance may hamper the growth of the hedgehog pathway inhibitors industry over the forecast period.

Overview

Increasing awareness about BCC and AML

The abnormal regulation of the Hedgehog pathway is largely linked to the development of cancer types such as BCC and AML. Several governmental and private nonprofit organizations are conducting programs to increase the awareness of the diagnosis and symptoms of BCC and AML , as well as the available treatment options. For instance, the Skin Cancer Foundation focuses on providing preventive care and support to patients. The primary focus of this awareness program is to educate people and spread awareness about the symptoms of various types of skin cancer, including BCC. Similarly, CancerCare campaign focuses on AML. This increasing awareness will lead to the expansion of the global hedgehog pathway inhibitors market at a CAGR of over 11% during the forecast period.

Development of repurposed formulations

Several companies are developing repurposed drug formulations to overcome the challenges associated with clinical development. It is an affordable and safe treatment approach to reuse the available approved non-cancer drugs as new anti-cancer treatments. For instance, HedgePath Pharmaceuticals Inc. in collaboration with Mayne Pharma Group Ltd. developed a repurposed formulation, named SUBA Itraconazole. It is a drug approved by the US FDA to treat fungal infections, has been repurposed as a drug to improve the bioavailability of poorly soluble approved drugs . As the SUBA technology offers benefits such as reduced intra-patient/inter-patient viability, and reduced side effects, the sales of hedgehog pathway inhibitors will increase subsequently. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global hedgehog pathway inhibitors market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of a few major players, the global hedgehog pathway inhibitors market is moderately concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of few leading hedgehog pathway inhibitors manufacturers, that include F. Hoffmann-La Roche Ltd., Inhibitor Therapeutics Inc., MAX BioPharma Inc., Mayne Pharma Group Ltd., PellePharm Inc., Pfizer Inc., Sun Pharmaceutical Industries Ltd.

Also, the hedgehog pathway inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • BCC - Market size and forecast 2018-2023
  • AML - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 08: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 09: MARKET TRENDS

  • Development of repurposed formulations
  • Strategic alliances
  • Funding for cancer-related research

PART 10: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 11: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • F. Hoffmann-La Roche Ltd.
  • Inhibitor Therapeutics Inc.
  • MAX BioPharma Inc.
  • Mayne Pharma Group Ltd.
  • PellePharm Inc.
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.

PART 12: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 13: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: BCC - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: BCC - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: AML - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: AML - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Impact of drivers and challenges
  • Exhibit 43: Vendor landscape
  • Exhibit 44: Landscape disruption
  • Exhibit 45: Vendors covered
  • Exhibit 46: Vendor classification
  • Exhibit 47: Market positioning of vendors
  • Exhibit 48: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 49: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 50: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 51: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 52: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 53: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 54: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 55: Inhibitor Therapeutics Inc. - Vendor overview
  • Exhibit 56: Inhibitor Therapeutics Inc. - Organizational developments
  • Exhibit 57: Inhibitor Therapeutics Inc. - Key offerings
  • Exhibit 58: Inhibitor Therapeutics Inc. - Key customers
  • Exhibit 59: MAX BioPharma Inc. - Vendor overview
  • Exhibit 60: MAX BioPharma Inc. - Organizational developments
  • Exhibit 61: MAX BioPharma Inc. - Key offerings
  • Exhibit 62: MAX BioPharma Inc. - Key customers
  • Exhibit 63: Mayne Pharma Group Ltd. - Vendor overview
  • Exhibit 64: Mayne Pharma Group Ltd. - Business segments
  • Exhibit 65: Mayne Pharma Group Ltd. - Organizational developments
  • Exhibit 66: Mayne Pharma Group Ltd. - Geographic focus
  • Exhibit 67: Mayne Pharma Group Ltd. - Segment focus
  • Exhibit 68: Mayne Pharma Group Ltd. - Key offerings
  • Exhibit 69: Mayne Pharma Group Ltd. - Key customers
  • Exhibit 70: PellePharm Inc. - Vendor overview
  • Exhibit 71: PellePharm Inc. - Organizational developments
  • Exhibit 72: PellePharm Inc. - Key offerings
  • Exhibit 73: PellePharm Inc. - Key customers
  • Exhibit 74: Pfizer Inc. - Vendor overview
  • Exhibit 75: Pfizer Inc. - Business segments
  • Exhibit 76: Pfizer Inc. - Organizational developments
  • Exhibit 77: Pfizer Inc. - Geographic focus
  • Exhibit 78: Pfizer Inc. - Segment focus
  • Exhibit 79: Pfizer Inc. - Key offerings
  • Exhibit 80: Pfizer Inc. - Key customers
  • Exhibit 81: Sun Pharmaceutical Industries Ltd. - Vendor overview
  • Exhibit 82: Sun Pharmaceutical Industries Ltd. - Product segments
  • Exhibit 83: Sun Pharmaceutical Industries Ltd. - Organizational developments
  • Exhibit 84: Sun Pharmaceutical Industries Ltd. - Geographic focus
  • Exhibit 85: Sun Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 86: Sun Pharmaceutical Industries Ltd. - Key customers
  • Exhibit 87: Validation techniques employed for market sizing
  • Exhibit 88: Definition of market positioning of vendors